

Obatoclox Regulates the Proliferation and Fusion of Osteoclast Precursors through the Inhibition of ERK Activation by RANKL

Ju Hee Oh^{1,2}, Jae Yoon Lee^{1,2}, Jin Hyeong Park¹, Jeong Hyeon No¹, and Na Kyung Lee^{1,*}

Obatoclox, a pan-Bcl2 inhibitor, shows antitumor activities in various solid malignancies. Bcl2-deficient mice have shown the importance of Bcl2 in osteoclasts, as the bone mass of the mice was increased by the induced apoptosis of osteoclasts. Despite the importance of Bcl2, the effects of obatoclox on the proliferation and differentiation of osteoclast precursors have not been studied extensively. Here, we describe the anti-proliferative effects of obatoclox on osteoclast precursors and its negative role on fusion of the cells. Stimulation with low doses of obatoclox significantly suppressed the proliferation of osteoclast precursors in a dose-dependent manner while the apoptosis was markedly increased. Its stimulation was sufficient to block the activation of ERK MAP kinase by RANKL. The same was true when PD98059, an ERK inhibitor, was administered to osteoclast precursors. The activation of JNK1/2 and p38 MAP kinase, necessary for osteoclast differentiation, by RANKL was not affected by obatoclox. Interestingly, whereas the number of TRAP-positive mononuclear cells was increased by both obatoclox and PD98059, fused, multinucleated cells larger than 100 μm in diameter containing more than 20 nuclei were completely reduced. Consistently, obatoclox failed to regulate the expression of osteoclast marker genes, including c-Fos, TRAP, RANK and CtsK. Instead, the expression of DC-STAMP and Atp6v0d2, genes that regulate osteoclast fusion, by RANKL was significantly abrogated by both obatoclox and PD98059. Taken together, these results suggest that obatoclox down-regulates the proliferation and fusion of osteoclast precursors through the inhibition of the ERK1/2 MAP kinase pathway.

INTRODUCTION

Bone undergoes a remodeling process that is efficiently controlled by the functional balance of bone formation by osteoblasts and destruction of mineralized bone matrix by osteoclasts (Harada and Rodan, 2003; Teitelbaum, 2000). While osteoblasts are derived from a mesenchymal lineage, osteoclasts are from hemopoietic progenitors of the monocyte/macrophage lineage (Harada and Rodan, 2003; Teitelbaum, 2000). The binding of receptor activator of nuclear factor- κB (NF- κB) ligand (RANKL) to its receptor, RANK, on osteoclast precursors is critical for osteoclast differentiation (Anderson et al., 1997; Wong et al., 1997). The elevation in numbers and/or activity of osteoclasts causes bone-related diseases such as Paget's disease, osteoporosis and lytic bone metastasis (Boyle et al., 2003; Rodan and Martin, 2000).

The activation of RANK by RANKL leads to distinct signaling cascades mediated by c-Jun N-terminal Kinase 1/2 (JNK1/2), p38 and extracellular signal-regulated kinase 1/2 (ERK1/2) MAP kinases regulated by the activation of MEK1 in osteoclast precursors, which are critical for RANKL-induced osteoclast differentiation (Boyle et al., 2003; David et al., 2002; Li et al., 2002; Wei et al., 2002). In particular, the ERK1/2 MAP kinase pathway is involved in the proliferation of a variety of cell types (Yang et al., 2010). p38 MAP kinase activation results in the downstream expression of several osteoclast marker genes, c-Fos, tartrate-resistant acid phosphatase (TRAP, encoded by *Acp5*) and cathepsin K (CtsK) during differentiation (Li et al., 2002; Mansky et al., 2002).

For the maturation of osteoclasts and for their bone-resorbing function, osteoclast precursors become from mononuclear cells to matured, multinucleated cells through a cell-cell fusion process (Blare, 1998; Vignery, 2000). Molecules participating in the fusion can be divided into two types: RANKL-independent molecules and RANKL-dependent molecules (Xing et al., 2012; Zhang et al., 2014). Whereas CD44 and TREM2 are not regulated by RANKL (de Vries et al., 2005; Kukita et al., 2004; Xing et al., 2012), CD9/CD81, ATP6v0d2, and DC-STAMP have been shown to be regulated by it (Kim et al., 2008; Kukita et al., 2004; Ishii et al., 2006).

Dendritic cell-specific transmembrane protein (DC-STAMP) and the d2 isoform of vacuolar (H^+) ATPase (v-ATPase) Vo domain (Atp6v0d2) are known to be key regulators for osteoclast maturation, and the deficiency of DC-STAMP or Atp6v0d2 leads to osteopetrosis in mice (Kim et al., 2008; Kukita et al.,

¹Department of Biomedical Laboratory Science, College of Medical Sciences, Soonchunhyang University, Chungnam, 336-745, Korea, ²These authors contributed equally to this work.

*Correspondence: nlee@sch.ac.kr

Received 11 December, 2014; revised 1 January, 2015; accepted 5 January, 2015; published online 4 February, 2015

Keywords: ERK1/2 MAP kinase, fusion, obatoclox, osteoclast precursors, proliferation

2004; Lee et al., 2006). Dendritic cell-specific transmembrane protein (DC-STAMP), discovered in human dendritic cells (DCs), is preferentially expressed in osteoclasts rather than DCs and macrophages (Hartgers et al., 2000; Kukita et al., 2004; Rho et al., 2002; Staeger et al., 2001; Yagi et al., 2005). Multiple isoforms of some subunits in V-ATPase, including B, C, E, and G of V1 and a and d of V0, have been identified in various tissues and cell types (Lee et al., 2006; Nishi et al., 2003; Wu et al., 2009). A 38-kDa protein, Atp6v0d2 (d2), has been found to be expressed in various mammalian tissues and is the most abundant in osteoclasts (Nishi et al., 2003; Wu et al., 2009). This subunit may also contribute to the efficient coupling of ATP hydrolysis of V1 and proton translocation of V0 (Nishi et al., 2003; Wu et al., 2009).

Obatoclox, a synthetic derivative of bacterial prodiginines, binds to all anti-apoptotic Bcl-2 family members and has a role as a pan-Bcl-2 inhibitor (Kim et al., 2014; Konopleva et al., 2008). It has already been used in early clinical trials and has been widely tested in solid malignancies and lymphoma (Campa's et al., 2006; Kim et al., 2014; Konopleva et al., 2008; Trudel et al., 2007). We have recently, for the first time, demonstrated that obatoclox stimulates apoptosis through the suppression of Bcl2A1 by insulin and inhibits the proliferation of osteoclast precursors (Lee and Lee, 2014). Thus, the effects of obatoclox on the proliferation and differentiation of osteoclast precursors have not been well-defined yet.

Based on this earlier report, our present study aimed at investigating the potential role and regulatory mechanisms of obatoclox on proliferation and differentiation of osteoclast precursors. Ultimately, our data revealed that obatoclox suppresses the proliferation of osteoclast precursors by increasing apoptosis, while decreasing the cell fusion through the inhibition of the activation of ERK1/2 MAP kinase by RANKL, showing the potential of obatoclox for the treatment of several bone-related diseases in the future.

MATERIALS AND METHODS

Isolation of osteoclast precursors

Isolation of osteoclast precursors and the *in vitro* osteoclastogenesis experiment were performed as described previously (Choi et al., 2013). In brief, bone marrow cells were flushed out from the femurs of 4-6-week-old C57BL/6 mice with a sterile 21-gauge syringe and incubated in alpha-MEM media containing 10% FBS and 10 ng/ml M-CSF (R&D Systems). After 24 h, non-adherent cells were harvested and cultured in the presence of M-CSF (20 ng/ml) for 3 days. After washing out the non-adherent cells, adherent cells were used as osteoclast precursors.

Cell viability (MTT) assay

Cells were seeded in 96-well plates with 2×10^4 cells/well in complete culture medium. After 24 h, the cells were treated with indicated doses of obatoclox (Selleck Chemicals) in the presence or absence of RANKL (Peprotech) for 24 h. Cell viability was measured using the MTT (3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium bromide) assay kit (Sigma) and the absorbance was on a microplate reader (Bio-Rad) at 570 nm (Choi et al., 2013).

BrdU incorporation assay

The BrdU incorporation assay was performed as described previously (Lee and Lee, 2014). In brief, after 24 h of seeding with 2×10^4 cells/well in 96-well plates, the cells were treated

with obatoclox or PD98059 (Sigma, USA). Cell proliferation was assayed using the BrdU incorporation assay kit (Cell Signaling Technology) according to the manufacturer's instructions. BrdU was added 12 h before culture termination. At the end of culture, cells were fixed with fixing solution for 30 min at RT, rinsed twice with PBS, incubated with monoclonal anti-BrdU antibody for 1 h, followed by anti-mouse secondary antibody for 30 min. After the final wash, the substrate was added to the wells and then the stop solution was administered. The proportion of total cells incorporating BrdU into the nucleus was determined by reading the absorbance on a microplate reader (Bio-Rad) at 450 nm to calculate cell viability.

Apoptosis assay

Apoptosis was measured using the Annexin V Apoptosis Kit (BD Biosciences) in accordance with the manufacturer's instructions. Osteoclast precursors were seeded with 2×10^4 cells/well in 96-well plates and then treated with obatoclox or PD98059. The cells were then washed with cold PBSs, resuspended in $1 \times$ Annexin V binding buffer (BD Biosciences), and labeled with 10 μ l Annexin V-APC (BD Biosciences) for 15 min in the dark. After incubation, $1 \times$ binding buffer was added. The analyses were performed using a FACScan flow cytometer (Becton Dickinson) (Lee and Lee, 2014).

Western blot analyses

Western blotting was performed as described previously (Choi et al., 2013). In brief, osteoclast precursors stimulated with RANKL or obatoclox were lysed in lysis buffer and the supernatants were prepared by centrifugation, electrophoresed on a 10% SDS-polyacrylamide gel and blotted onto a polyvinylidene difluoride membrane. Immunoblotting was performed with antibodies (Abs) specific to phosphorylated ERK1/2 (p-ERK1/2), ERK1/2, phosphorylated JNK1/2 (p-JNK1/2), JNK1/2, phosphorylated p38 (p-p38), p38 MAP kinase (Cell Signaling Technology, USA), DC-STAMP, Atp6v0d2, and beta-actin (Santa Cruz Biotechnology, USA), followed by HRP-conjugated secondary antibodies and enhanced using an ECL detection kit (Amersham Biosciences).

In vitro osteoclastogenesis

For the osteoclast formation assay, the cells isolated from the femur of mice were further cultured in the presence of 200 ng/ml of RANKL and 30 ng/ml of M-CSF. After 3 days, the cells were fixed, stained for tartrate-resistant acid phosphatase (TRAP) using the TRAP staining kit (Sigma). TRAP-positive multinucleated cells (TRAP⁺ MNCs) larger than 100 μ m in diameter containing more than 20 nuclei and TRAP⁺ mononuclear cells were counted, and the number was presented as relative percentage (%).

Real-time PCR

Total RNAs isolated from cells were reverse transcribed using SuperscriptIII reverse transcriptase (Invitrogen) according to the manufacturer's protocol. Real-time PCRs were performed with the Brilliant UltraFast SYBR Green QPCR Master Mix (Agilent Technologies) and specific primers for target genes and HPRT (for endogenous control) from QIAGEN in triplicate on an MX3000 instrument (Agilent Technologies). HPRT was used for the normalization of all quantitation (Kim and Lee, 2014).

Statistical analysis

The results are presented by mean \pm SD of triplicates from at least three independent experiments. Statistical analyses were




Fig. 1. Effect of obatoclox on cell viability. (A) Osteoclast precursors were incubated with the indicated concentrations of obatoclox for 24 h. The cytotoxicity of obatoclox was determined using the MTT assay kit. (B) The indicated concentrations of obatoclox were treated into the osteoclast precursors for 48 h. Then, cell proliferation was measured using

the BrdU incorporation assay kit. (C) The increase of apoptosis by the indicated concentrations of obatoclox after 48 h of treatment on osteoclast precursors. Apoptosis was measured using the Annexin V Apoptosis Kit as described in "Materials and Methods". Results are representative of at least three independent experiments. * $p < 0.05$ and ** $p < 0.005$ vs. non-treated cells.

determined using Student's *t*-test. $P < 0.05$ was considered significant.

RESULTS

Obatoclox inhibits the proliferation of osteoclast precursors by inducing apoptosis

Prior to investigating the role of obatoclox on the proliferation and differentiation of osteoclast precursors, we first examined the cytotoxicity of obatoclox. Whereas low doses (10 nM and 100 nM) of obatoclox did not show a cytotoxic effect, the higher dose (1000 nM) of obatoclox completely decreased cell viability (Fig. 1A). The BrdU incorporation assay showed that the low dose of obatoclox has impressive inhibitory effects on their proliferation (Fig. 1B). On the contrary, obatoclox significantly increased the number of apoptotic cells in a dose-dependent manner (Fig. 1C). These results demonstrate that obatoclox inhibits cell proliferation by inducing the apoptosis of osteoclast precursors.

ERK MAP kinase activation is involved in the proliferation and apoptosis of osteoclast precursors

To gain insight into how obatoclox regulates proliferation of osteoclast precursors, we examined whether obatoclox regulates the activation of MAP kinases by RANKL. As expected, RANKL effectively activated ERK1/2, JNK1/2, and p38 MAP kinases (Fig. 2A). Interestingly, pretreatment with obatoclox dramatically inhibited the activation of ERK1/2 by RANKL. However, the activation of JNK1/2 and p38 MAP kinases was not affected (Fig. 2A).

To verify whether the inhibition of ERK1/2 MAP kinase by obatoclox is involved in the proliferation of the cells, an inhibitor of ERK, PD98059, was administered. Whereas RANKL alone failed to regulate cell proliferation and apoptosis, pretreatment with PD98059 effectively suppressed cell proliferation and increased apoptosis in the presence of RANKL, just as obatoclox did (Figs. 2B and 2C). These results suggest that obatoclox regulates the proliferation and apoptosis of osteoclast precursors through the inhibition of ERK1/2 MAP kinase.

Obatoclox down-regulates the fusion of osteoclast precursors by blocking the ERK1/2 signaling pathway

It is known that the activation of ERK1/2 MAP kinase is important for the osteoclast differentiation induced by RANKL (Boyle et al., 2003). Prior to determining whether the inhibition of ERK1/2 MAP kinase by obatoclox affects osteoclast differentiation, we first examined the effect of PD98059 on the cells. Stimulation with RANKL markedly induced osteoclast differentiation (Figs. 3A and 3D). However, pretreatment with PD98059




Fig. 2. ERK MAP kinase activation is involved in the proliferation and apoptosis of osteoclast precursors. (A) Osteoclast precursors were pretreated with or without 100 nM of obatoclox before 2 h of RANKL treatment for the indicated times. Total proteins were isolated and then subjected to Western blot analyses using MAP kinases-specific antibodies (left). Protein bands were quantified by densitometry, and the level of phosphorylated ERK1/2 MAP kinase was normalized to that of ERK1/2 (right). (B and C) Osteoclast precursors were pretreated with obatoclox (100 nM, Ob) before 2 h or PD98059 (10 μ M, PD) before 30 min of RANKL treatment for 48 h. Then, cell proliferation (B) and apoptosis (C) were measured as described in Materials and Methods. Results are representative of at least three independent experiments. * $p < 0.05$ and ** $p < 0.005$ vs. non-treated cells.

completely suppressed the number of fused, multinucleated cells larger than 100 μ m in diameter containing more than 20 nuclei, whereas the number of TRAP-positive mononuclear cells was increased (Figs. 3B and 3C). Obatoclox showed a similar effect to the ERK inhibitor (Figs. 3E and 3F). However, obatoclox alone failed to regulate osteoclast differentiation (Fig. 3D). These results indicate that obatoclox suppresses the fusion of osteoclast precursors into multinucleated cells through the inhibition of ERK1/2 MAP kinase.




Fig. 3. Obatoclox down-regulates the fusion of osteoclast precursors through the ERK1/2 MAP kinase. (A-C) Osteoclast precursors were pretreated with 10 μ M of PD98059 for 30 min and then RANKL for 3 days. TRAP staining was performed (original magnification, \times 100) (A) and TRAP⁺ mononuclear cells (B) or TRAP⁺ MNCs larger than 100 μ m in diameter containing more than 20 nuclei (C) were counted and presented as relative percentage (%). * p < 0.05 and ** p < 0.005 vs. RANKL-treated cells. (D-F) As in (A-C), except that 100 nM or 200 nM of obatoclox (Ob) for 2 h was pretreated instead of PD98059.




Fig. 4. Obatoclox decreases the expression of DC-STAMP and *Atp6v0d2*. (A) Isolated osteoclast precursors were pretreated with 100 nM of obatoclox (Ob) for 2 h and then RANKL (R) for the indicated times. Total RNA was isolated from the cells and then subjected to real-time PCR as described in “Materials and Methods”. All quantitation was normalized to an HPRT and the fold increase in the stimulated cells was compared with untreated cells as shown. Results are representative of at least three independent experiments. * p < 0.05 and ** p < 0.005 vs. non-treated cells. # p < 0.05 vs. RANKL-treated cells for 24 h. (B) Osteoclast

precursors were pretreated with 10 μ M of PD98059 (PD) for 30 min then treated with RANKL (R) for 3 days. 30 μ g of total cell lysates was analyzed by Western blot analysis.

Obatoclox suppresses the expression of DC-STAMP and *Atp6v0d2* by RANKL

The result that obatoclox down-regulated the fusion of osteoclast precursors led us to hypothesize that obatoclox may control the expression of *DC-STAMP* and *Atp6v0d2*, which are both known to regulate the cell-cell fusion (Kukita et al., 2004; Lee et al., 2006), of osteoclast precursors. To verify that, we examined the expression of osteoclast marker genes including *DC-STAMP* and *Atp6v0d2* was affected by obatoclox treatment. While RANKL effectively induced the expression of the osteoclast marker genes, *c-Fos*, *TRAP*, *RANK*, and *CtsK*, pretreatment with obatoclox did not affect their expression (Fig. 4A). However, the expression of *DC-STAMP* and *Atp6v0d2* induced by RANKL stimulation was abolished by obatoclox pretreatment (Fig. 4A).

To determine whether this result was caused by the inhibition of ERK1/2 MAP kinase, cells were pretreated with PD98059. Western blot analyses showed that pretreatment with PD98059 completely inhibited the expression of *DC-STAMP* and *Atp6v0d2* induced by RANKL (Fig. 4B), which strongly supports that obatoclox regulates the fusion of osteoclast precursors

through the ERK 1/2 MAP kinase pathways, a finding consistent with previous data (Fig. 3). Taken together, these data suggest that obatoclox regulates the proliferation and fusion of osteoclast precursors negatively through the inhibition of the ERK1/2 MAP kinase pathway by RANKL (Fig. 5).

DISCUSSION

The Bcl2/Bax ratio determines cell fate: proliferation or apoptosis. Whereas an enhancement of Bcl2, an anti-apoptotic protein, promotes cell proliferation, Bax, a pro-apoptotic protein, activates caspase3 and induces apoptosis (Hockenbery et al., 1993; Yamashita et al., 2008). *Bcl2*^{-/-} mice showed increased bone mass due to the induced apoptosis of osteoclasts; however, proliferation and differentiation of osteoblasts are not affected (Yamashita et al., 2008). This suggests that Bcl2 plays a critical anti-apoptotic role in osteoclasts rather than osteoblasts. Obatoclox, a pan-Bcl2 inhibitor, has been applied in various solid malignancies and lymphoma, and exerted antitumor activities (Hwang et al., 2010; Paik et al., 2010). Despite the importance of Bcl2 in osteoclasts, the effects of obatoclox on the




Fig. 5. The regulatory mechanisms model of the proliferation and fusion of osteoclast precursors by obatoclox. Obatoclox inhibits the ERK1/2 MAP kinase activation by RANKL, thus suppressing the proliferation and fusion of osteoclast precursors.

proliferation and differentiation of osteoclast precursors have not been well-defined. We have recently shown that obatoclox suppresses their proliferation by insulin through the inhibition of apoptosis (Lee and Lee, 2014). Based on this previous study, the present study aimed to assess the potential of obatoclox on the proliferation and differentiation of osteoclast precursors. Here, we describe the anti-proliferative effects of obatoclox on osteoclast precursors and its negative role in their fusion.

Stimulation with low doses of obatoclox significantly suppressed the cell proliferation in a dose-dependent manner, while markedly increasing the apoptosis of osteoclast precursors. These functions were found to be through ERK MAP kinase signaling since its stimulation was sufficient to block the activation of ERK MAP kinase by RANKL and these obvious effects were also observed when PD98059, an ERK inhibitor, was administered in the cells.

The ERK MAP kinase signaling pathway seems to be related to two distinct mechanisms in osteoclast precursors: on one hand, by stimulating proliferation through the down-regulation of apoptosis, and on the other hand, by up-regulating the cell fusion, thus contributing to osteoclastogenesis. Pretreatment with either obatoclox or PD98059 dramatically reduced the cell-cell fusion by RANKL stimulation via blocking of the ERK signaling pathway. However, TRAP-positive mononuclear cells were relatively increased compared to when RANKL alone was treated since RANKL markedly increased the number of multinucleated cells (TRAP⁺ MNCs) larger than 100 μm in diameter containing more than 20 nuclei although obatoclox and PD98059 inhibited the proliferation of osteoclast precursors.

Interestingly, the activation of JNK1/2 and p38 MAP kinase, necessary for osteoclast differentiation, by RANKL was not affected by obatoclox. These results are consistent with the finding that obatoclox failed to regulate the expression of osteoclast marker genes, including c-Fos, TRAP, RANK and CtsK. Instead, the expression of DC-STAMP and Atp6v0d2 by RANKL was significantly reduced by obatoclox, which was through the ERK pathway since PD98059 completely abrogated the expression of these two proteins. These results imply that obatoclox may work during the late stage of osteoclastogenesis

undergoing cell-cell fusion, rather than the earlier stage of osteoclast differentiation.

Still, there are the subjects of further research: 1) whether obatoclox results in the arrest of the cell cycle in osteoclast precursors, and 2) whether or how Bcl2 and ERK signaling is connected in the regulation of the proliferation and differentiation of the cells. In the previous study, cyclinD1, a cell cycle regulator, was affected by insulin stimulation in osteoclast precursors, and thus enhanced cell proliferation (Lee and Lee, 2014). This shows that cyclinD1 may be a target of obatoclox through the ERK signaling pathway. It needs to be further studied.

Continued investigation into the signaling and molecular mechanisms of obatoclox on osteoclast precursors could contribute to the understanding of bone metabolism and give hints toward novel targets for treatment.

ACKNOWLEDGMENTS

This work was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2010-0025761) and the Soonchunhyang University Research Fund.

REFERENCES

- Anderson, D.M., Maraskovsky, E., Billingsley, W.L., Dougall, W.C., Tometsko, M.E., Roux, E.R., Teepe, M.C., DuBose, R.F., Cosman, D., and Galibert, L. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature* 390, 175-179.
- Blair, H.C. (1998). How the osteoclast degrades bone. *Bioessays* 20, 837-848.
- Boyle, W.J., Simonet, W.S., and Lacey, D.L. (2003). Osteoclast differentiation and activation. *Nature* 423, 337-342.
- Campa's, C., Cosials, A.M., Barragán, M., Iglesias-Serret, D., Santidrián, A.F., Coll-Mulet, L., de Frias, M., Domingo, A., Pons, G., and Gil, J. (2006). Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. *Exp. Hematol.* 34, 1663-1669.
- Choi, J., Choi, S.Y., Lee, S.Y., Lee, J.Y., Kim, H.S., Lee, S.Y., and Lee, N.K. (2013). Caffeine enhances osteoclast differentiation and maturation through p38 MAP kinase/Mitf and DC-STAMP/CtsK and TRAP pathway. *Cell. Signal.* 25, 1222-1227.
- David, J.P., Sabapathy, K., Hoffmann, O., Idarraga, M.H., and Wagner, E.F. (2002). JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. *J. Cell Sci.* 115, 4317-4325.
- de Vries, T.J., Schoenmaker, T., Beertsen, W., van der Neut, R., and Everts, V. (2005). Effect of CD44 deficiency on *in vitro* and *in vivo* osteoclast formation. *J. Cell. Biochem.* 94, 954-966.
- Harada, S., and Rodan, G.A. (2003). Control of osteoblast function and regulation of bone mass. *Nature* 423, 349-355.
- Hartgers, F.C., Vissers, J.L., Looman, M.W., van Zoelen, C., Huffine, C., Figdor, C.G., and Adema, G.J. (2000). DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. *Eur. J. Immunol.* 30, 3585-3590.
- Hockenbery, D.M., Oltvai, Z.N., Yin, X.M., Millman, C.L., and Korsmeyer, S.J. (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis. *Cell* 75, 241-251.
- Hwang, J.J., Kuruvilla, J., Mendelson, D., Pishvaian, M.J., Deeken, J.F., Siu, L.L., Berger, M.S., Viallet, J., and Marshall, J.L. (2010). Phase I dose finding studies of obatoclox (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. *Clin. Cancer Res.* 16, 4038-4045.
- Ishii, M., Iwai, K., Koike, M., Ohshima, S., Kudo-Tanaka, E., Ishii, T., Mima, T., Katada, Y., Miyatake, K., Uchiyama, Y., and Saeki, Y. (2006). RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. *J. Bone Miner. Res.* 21, 965-976.
- Kim, H.S., and Lee, N.K. (2014). Gene expression profiling in osteoclast precursors by insulin using microarray analysis. *Mol. Cells*

- 30, 827-832.
- Kim, K., Lee, S.H., Kim, J., Choi, Y., and Kim, N. (2008). NFATc1 induces osteoclast fusion via upregulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DCSTAMP). *Mol. Endocrinol.* 22, 176-185.
- Kim, P.S., Jochems, C., Grenga, I., Donahue, R.N., Tsang, K.Y., Gulley, J.L., Schlom, J., and Farsaci, B. (2014). Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclox), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. *J. Immunol.* 192, 2622-2633.
- Konopleva, M., Watt, J., Contractor, R., Tsao, T., Harris, D., Estrov, Z., Bornmann, W., Kantarjian, H., Viallet, J., Samudio, I., et al. (2008). Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclox). *Cancer Res.* 68, 3413-3420.
- Kukita, T., Wada, N., Kukita, A., Kakimoto, T., Sandra, F., Toh, K., Nagata, K., Iijima, T., Horiuchi, M., Matsusaki, H., et al. (2004). RANKL-induced DC-STAMP is essential for osteoclastogenesis. *J. Exp. Med.* 200, 941-946.
- Lee, J.Y., and Lee, N.K. (2014). Up-regulation of cyclinD1 and Bcl2A1 by insulin is involved in osteoclast proliferation. *Life Sci.* 114, 57-61.
- Lee, S.H., Rho, J., Jeong, D., Sul, J.Y., Kim, T., Kim, N., Kang, J.S., Miyamoto, T., Suda, T., Lee, S.K., et al. (2006). v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. *Nat. Med.* 12, 1403-1409.
- Li, X., Udagawa, N., Itoh, K., Suda, K., Murase, Y., and Nishihara, T. (2002). p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. *Endocrinology* 143, 3105-3113.
- Mansky, K.C., Sankar, U., Han, J., and Ostrowski, M.C. (2002). Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF- B ligand signaling. *J. Biol. Chem.* 277, 11077-11083.
- Nishi, T., Kawasaki-Nishi, S., and Forgac, M. (2003). Expression and function of the mouse V-ATPase d subunit isoforms. *J. Biol. Chem.* 278, 46396-46402.
- Paik, P.K., Rudin, C.M., Brown, A., Rizvi, N.A., Takebe, N., Travis, W., James, L., Ginsberg, M.S., Juergens, R., Markus, S., et al. (2010). A phase I study of obatoclox mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. *Cancer Chemother. Pharmacol.* 66, 1079-1085.
- Rho, J., Altmann, C.R., Socci, N.D., Merkov, L., Kim, N., So, H., Lee, O., Takami, M., Brivanlou, A.H., and Choi, Y. (2002). Gene expression profiling of osteoclast differentiation by combined suppression subtractive hybridization (SSH) and cDNA microarray analysis. *DNA Cell. Biol.* 21, 541-549.
- Rodan, G.A., and Martin, T.J. (2000). Therapeutic approaches to bone diseases. *Science* 289, 1508-1514.
- Staeger, H., Brauchlin, A., Schoedon, G., and Schaffner, A. (2001). Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages. *Immunogenetics* 53, 105-113.
- Teitelbaum, S.L. (2000). Bone resorption by osteoclasts. *Science* 289, 1504-1508.
- Trudel, S., Li, Z.H., Rauw, J., Tiedemann, R.E., Wen, X.Y., and Stewart, A.K. (2007). Preclinical studies of the pan-Bcl inhibitor obatoclox (GX015-070) in multiple myeloma. *Blood* 109, 5430-5438.
- Vignery, A. (2000). Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. *Int. J. Exp. Pathol.* 81, 291-304.
- Wei, S., Wang, M.W., Teitelbaum, S.L., and Ross, F.P. (2002). Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. *J. Biol. Chem.* 277, 6622-6630.
- Wong, B.R., Josien, R., Lee, S.Y., Sauter, B., Li, H.L., Steinman, R.M., and Choi, Y. (1997). TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. *J. Exp. Med.* 186, 2075-2080.
- Wu, H., Xu, G., and Li, Y.P. (2009). Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. *J. Bone Miner. Res.* 24, 871-885.
- Xing, L., Xiu, Y., and Boyce, B.F. (2012). Osteoclast fusion and regulation by RANKL-dependent and independent factors. *World J. Orthop.* 3, 212-222.
- Yamashita, J., Datta, N.S., Chun, Y.H., Yang, D.Y., Carey, A.A., Kreider, J.M., Goldstein, S.A., and McCauley, L.K. (2008). Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. *J. Bone Miner. Res.* 23, 621-632.
- Yang, J., Zhang, X., Wang, W., and Liu, J. (2010). Insulin stimulates osteoblast proliferation and differentiation through ERK and PI3K in MG-63 cells. *Cell Biochem. Funct.* 28, 334-341.
- Zhang, C., Dou, C.E., Xu, J., and Dong, S. (2014). DC-STAMP, the key fusion-mediating molecule in osteoclastogenesis. *J. Cell. Physiol.* 229, 1330-1335.